References
Abraham K, Geusau A, Tosun Y, Helge H, Bauer S, Brockmoller J. 2002. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction. Clin Pharmacol Ther 72:163-174.
Abraham K, Krowke R, Neubert D. 1988. Pharmacokinetics and biological activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. 1: Dose-dependent tissue distribution and induction of hepatic ethoxyresorufin O-deethylase in rats following a single injection. Arch Toxicol 62(5):359-368.
Allen JR, Van Miller JP, Norback DH. 1975. Tissue distribution, excretion and biological effects of [14C]tetrachlorodibenzo-p-dioxin in rats. Food Cosmet Toxicol 13:501-505.
Andersen ME, Birnbaum LS, Barton HA, Eklund C. 1997. Regional hepatic CTP1A1 and CYP1A2 induction with 2,3,7,8-tetra-chlorodibenzo-p-dioxin evaluated with a multicompartment geometric model of hepatic zonation. Toxicol Appl Pharmacol 144:145-155.
Andersen ME, Mills JJ, Gargas ML, Kedderis L, Birnbaum LS, Neubert D, et al. 1993. Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment. Risk Anal 13:25-36.
Anzenbacher P, Anzenbacherova E. 2001. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 58:737-747.
Aylward LL, Brunet RC, Carrier G, Hays SM, Cushing CA, Needham LL, et al. 2005. Concentration-dependent TCDD elimination kinetics in humans: toxicokinetic modeling for moderately to highly exposed adults from Seveso, Italy, and Vienna, Austria, and impact on dose estimates for the NIOSH cohort. J Expo Anal Environ Epidemiol 15:51-65.
Aylward LL, Hays SM, Karch NJ, Paustenbach DJ. 1996. Relative suceptibility of animals and humans to the cancer hazard posed by 2,3,7,8-tetrachlorodibenzo-p-dioxin using internal measures. Environ Sci Technol 30:3534-3543.
Carrier G, Brunet RC, Brodeur J. 1995a. Modeling of the toxicokinetics of polychlorinated dibenzo-p-dioxins and dibenzofuranes in mammalians, including humans. II: Kinetics of absorption and disposition of PCDDs/PCDFs. Toxicol Appl Pharmacol 131:267-276.
Carrier G, Brunet RC, Brodeur J. 1995b. Modeling of the toxicokinetics of polychlorinated dibenzo-p-dioxins and dibenzofurans in mammalians, including humans. Toxicol Appl Pharmacol 131:253-266.
Cheng PY, Morgan ET. 2001. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2:165-183.
Crump KS, Canady R, Kogevinas M. 2003. Meta-analysis of dioxin cancer dose response for three occupational cohorts. Environ Health Perspect 111:681-687.
DeVito MJ, Birnbaum LS. 1995. Dioxins: model chemicals for assessing receptor-mediated toxicity. Toxicology 102:115-123.
Diliberto JJ, Burgin DE, Birnbaum LS. 1999. Effects of CYP1A2 on disposition of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, and 2,2’,4,4’,5,5’-hexachloro-biphenyl in CYP1A2 knockout and parental (C57BL/6N and 129/Sv) strains of mice. Toxicol Appl Pharmacol 159:52-64.
Diliberto JJ, DeVito MJ, Ross DG, Birnbaum LS. 2001. Subchronic exposure of [3H]- 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in female B6C3F1 mice: relationship of steady-state levels to disposition and metabolism. Toxicol Sci 61(2):241-255.
Emond C, Birnbaum LS, DeVito M. 2004. Physiologically based pharmacokinetic model for developmental exposures to TCDD in the rat. Toxicol Sci 80:115-133.
Emond C, Michalek JE, Birnbaum LS, Devito MJ. 2005. Comparison of the use of a physiologically based pharmacokinetic model and a classical pharmacokinetic model for dioxin exposure assessments. Environ Health Perspect 113:1666-1668.
Flesch-Janys D, Becher H, Gurn P, Jung D, Konietzko J, Manz A, et al. 1996. Elimination of polychlorinated dibenzo-p-dioxins and dibenzofurans in occupationally exposed persons. J Toxicol Environ Health 47:363-378.
Hakk H, Diliberto JJ. 2002. Comparison of overall metabolism of 2,3,7,8-TCDD in CYP1A2 (−/−) knockout and C57BL/6N parental strains on mice. Organohalogen Compounds 55:461-464.
Kedderis LB, Diliberto JJ, Linko P, Goldstein JA, Birnbaum LS. 1991. Disposition of 2,3,7,8-tetrabromodibenzo-p-dioxin and 2,3,7,8,-tetrachlorodibenzo-p-dioxin in the rat: biliary excretion and induction of cytochrome CYP1A1 and CYP1A2. Toxicol Appl Pharmacol 111:163-172.
Kohn MC, Sewall CH, Lucier GW, Portier CJ. 1996. A mechanistic model of effects of dioxin on thyroid hormones in the rat. Toxicol Appl Pharmacol 136:29-48.
Lakshmanan MR, Campbell BS, Chirtel SJ, Ekarohita N, Ezekiel M. 1986. Studies on the mechanism of absorption and distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. J Pharmacol Exp Ther 239:673-677.
Maruyama W, Yoshida K, Tanaka T, Nakanishi J. 2002. Possible range of dioxin concentration in human tissues: simulation with a physiologically based model. J Toxicol Environ Health A 65:2053-2073.
Michalek JE, Pirkle JL, Needham LL, Patterson DG, Caudill SP, Tripathi RC, et al. 2002. Pharmacokinetics of 2,3,7,8-tetra-chlorodibenzo-p-dioxin in Seveso adults and veterans of operation Ranch Hand. J Expo Anal Environ Epidemiol 12:44-53.
Michalek JE, Tripathi RC. 1999. Pharmacokinetics of TCDD in veterans of Operation Ranch Hand: 15-year follow-up. J Toxicol Environ Health A 57:369-378. [CrossRef].
Moser GA, McLachlan MS. 2002. Partitioning of polychlorinated biphenyls and hexachlorobenzene into human faeces. Chemosphere 46:449-457.
Olson JR, McGarrigle BP, Gigliotti PJ, Kumar S, McReynolds JH. 1995. Hepatic uptake and metabolism of 2,3,7,8-tetra-chlorodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzofuran. Fundam Appl Toxicol 22:631-640.
Pinsky PF, Lorber MN. 1998. A model to evaluate past exposure to 2,3,7,8-TCDD. J Expo Anal Environ Epidemiol 8:187-206.
Piper WN, Rose JQ, Gehring PJ. 1973. Excretion and tissue distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. Environ Health Perspect 5:241-244.
Pohjanvirta R, Vartiainen T, Uusi-Rauva A, Monkkonen J, Tuomisto J. 1990. Tissue distribution, metabolism, and excretion of 14C-TCDD in a TCDD-susceptible and a TCDD-resistant rat strain. Pharmacol Toxicol 66:93-100.
Poiger H, Schlatter C. 1985. Influence of phenobarbital and TCDD on the hepatic metabolism of TCDD in the dog. Experientia 41:376-378.
Rose JQ, Ramsey JC, Wentzler TH, Hummel RA, Gehring PJ. 1976. The fate of 2,3,7,8-tetrachlorodibenzo-p-dioxin following single and repeated oral doses to the rat. Toxicol Appl Pharmacol 36:209-226.
Salvan A, Thomaseth K, Bortot P, Sartori N. 2001. Use of a toxico-kinetic model in the analysis of cancer mortality in relation to the estimated absorbed dose of dioxin (2,3,7,8-tetra-chlorodibenzo-p-dioxin, TCDD). Sci Total Environ 274:21-35.
Santostefano MJ, Ross DG, Savas U, Jefcoate CR, Birnbaum LS. 1997. Differential time-course and dose-response relationships of TCDD-induced CYP1B1, CYP1A1, and CYP1A2 proteins in rats. Biochem Biophys Res Commun 233(1):20-24.
Santostefano MJ, Wang F, Richardson VM, Ross DG, Devito MJ, Birnbaum LS. 1998. A pharmacodynamic analysis of TCDD-induced cytochrome P450 gene expression in multiple tissues: dose- and time-dependent effects. Toxicol Appl Pharmacol 151:294-310.
Shinkyo R, Sakaki T, Ohta M, Inouye K. 2003. Metabolic pathways of dioxin by CYP1A1: species difference between rat and human CYP1A subfamily in the metabolism of dioxins. Arch Biochem Biophys 409:180-187.
Staskal DF, Diliberto JJ, Devito MJ, Birnbaum LS. 2005. Inhibition of human and rat CYP1A2 by TCDD and dioxin-like chemicals. Toxicol Sci 2005 84:225-231.
Steenland K, Deddens J, Piacitelli L. 2001. Risk Assessment for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) based on an epidemiologic study. Am J Epidemiol 154:451-458.
Steiner EC, Rey TD, McCroskey PS. 1990. Reference Guide for Simusolv. Midland, MI:Dow Chemical Co.
Tai HL, McReynolds JH, Goldstein JA, Eugster HP, Sengstag C, Alworth WL, et al. 1993. Cytochrome P4501A1 mediates the metabolism of 2,3,7,8-tetrachlorodibenzofuran in the rat and human. Toxicol Appl Pharmacol 123:34-42.
van der Molen GW, Kooijman SA, Michalek JE, Slob W. 1998. The estimation of elimination rates of persistent compounds: a re-analysis of 2,3,7,8-tetrachlorodibenzo-p-dioxin levels in Vietnam veterans. Chemosphere 37:1833-1844.
van der Molen GW, Kooijman BA, Wittsiepe J, Schrey P, Flesch-Janys D, Slob W. 2000. Estimation of dioxin and furan elimination rates with a pharmacokinetic model. J Expo Anal Environ Epidemiol 10:579-585.
Viluksela M, Duong TV, Stahl BU, Li X, Tuomisto J, Rozman KK. 1996. Toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in two substrains of male Long-Evans rats after intravenous injection. Fundam Appl Toxicol 31:184-191.
Walker NJ, Portier CJ, Lax SF, Crofts FG, Li Y, Lucier GW, et al. 1999. Characterization of the dose-response of CYP1B1, CYP1A1, and CYP1A2 in the liver of female Sprague-Dawley rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 154:279-286.
Wang X, Santostefano MJ, Devito MJ, Birnbaum LS. 2000. Extrapolation of a PBPK model for dioxins across dosage regimen, gender, strain, and species. Toxicol Sci 56:49-60.
Wang X, Santostefano MJ, Evans MV, Richardson VM, Diliberto JJ, Birnbaum LS. 1997. Determination of parameters responsible for pharmacokinetic behavior of TCDD in female Sprague-Dawley rats. Toxicol Appl Pharmacol 147:151-168.
Weber LW, Ernst SW, Stahl BU, Rozman K. 1993. Tissue distribution and toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats after intravenous injection. Fundam Appl Toxicol 21:523-534.
Last Updated: October 30, 2006